What does Filepharma Invest do?

Filepharma Invest is a holding company in Soignies. Private Limited, started on 29 November 2018, 1 establishment.

What is the address of Filepharma Invest?

The registered office of Filepharma Invest is located at Chaussée de Bruxelles 133, 7061 Soignies.

Is Filepharma Invest still active?

Yes. According to the CBE (30 October 2026) Filepharma Invest is active, legal situation “Normale toestand”, started on 29 November 2018.

Is Filepharma Invest registered on Peppol?

Yes, Filepharma Invest is registered on the Peppol network with ID 0208:0714928107.

What is the enterprise number of Filepharma Invest?

The enterprise number of Filepharma Invest is BE0714928107.

When was Filepharma Invest founded?

Filepharma Invest was founded on 29 November 2018.

Who are the directors of Filepharma Invest?

According to the 2025 annual accounts, the directors of Filepharma Invest are: Celine FILECCIA.

Is Filepharma Invest a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 29 November 2018; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Filepharma Invest make in 2025?

Filepharma Invest posted a profit after taxes of € 105,376 in financial year 2025.

What is the revenue of Filepharma Invest?

As a small company, Filepharma Invest is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 129,672.

Filepharma Invest (Private Limited) - Soignies

Dossier Filepharma Invest, printed on 30 October 2026 from databakkes.be/en/0714928107/filepharma-invest. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 29 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

Filepharma Invest from Soignies, company number BE0714928107, closed financial year 2025 with a result of € 105,376 after tax. For that financial year Filepharma Invest recorded a gross margin of € 129,672 and equity of € 439,736. Compared with financial year 2024, the result moved from € 74,919 to € 105,376. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 3, 2026.

What it is worth Growing

€ 439,736

▲ 26% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 105,376

▲ 41% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 21,268

▲ € 17,878 vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 15,000 paid out

14 % of the profit went to the shareholders, the rest stayed in the company.

Debts at end 2025

Bank debt ≈ 9 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 639,547

▼ 10% vs 2024

€ 68,424 is repaid this year. At this pace the long-term loan is gone in ≈ 9 years.

Owed to suppliers

€ 1,357

▲ 4% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 116,509 Gross margin 2022: € 116,509 First fiscal year in the series	€ 129,375 Gross margin 2023: € 129,375 ▲ 11% vs 2022 (€ 116,509) Favourable step	€ 124,583 Gross margin 2024: € 124,583 ▼ 4% vs 2023 (€ 129,375) Unfavourable step	€ 129,672 Gross margin 2025: € 129,672 ▲ 4% vs 2024 (€ 124,583) Favourable step	▲ 4%
Profit after taxes	€ 102,922 Profit after taxes 2022: € 102,922 First fiscal year in the series	€ 90,676 Profit after taxes 2023: € 90,676 ▼ 12% vs 2022 (€ 102,922) Unfavourable step	€ 74,919 Profit after taxes 2024: € 74,919 ▼ 17% vs 2023 (€ 90,676) Unfavourable step	€ 105,376 Profit after taxes 2025: € 105,376 ▲ 41% vs 2024 (€ 74,919) Favourable step	▲ 41%
Equity	€ 227,295 Equity 2022: € 227,295 First fiscal year in the series	€ 297,971 Equity 2023: € 297,971 ▲ 31% vs 2022 (€ 227,295) Favourable step	€ 349,361 Equity 2024: € 349,361 ▲ 17% vs 2023 (€ 297,971) Favourable step	€ 439,736 Equity 2025: € 439,736 ▲ 26% vs 2024 (€ 349,361) Favourable step	▲ 26%
Total debts	€ 887,087 Total debts 2022: € 887,087 First fiscal year in the series	€ 806,013 Total debts 2023: € 806,013 ▼ 9% vs 2022 (€ 887,087) Favourable step	€ 748,892 Total debts 2024: € 748,892 ▼ 7% vs 2023 (€ 806,013) Favourable step	€ 656,032 Total debts 2025: € 656,032 ▼ 12% vs 2024 (€ 748,892) Favourable step	▼ 12%
Cash	€ 12,557 Cash 2022: € 12,557 First fiscal year in the series	€ 347 Cash 2023: € 347 ▼ 97% vs 2022 (€ 12,557) Unfavourable step	€ 3,390 Cash 2024: € 3,390 ▲ € 3,043 vs 2023 (€ 347) Favourable step	€ 21,268 Cash 2025: € 21,268 ▲ € 17,878 vs 2024 (€ 3,390) Favourable step	▲ € 17,878
Land & buildings	€ 126,833 Land & buildings 2022: € 126,833 First fiscal year in the series	€ 120,458 Land & buildings 2023: € 120,458 ▼ 5% vs 2022 (€ 126,833) Unchanged	€ 114,083 Land & buildings 2024: € 114,083 ▼ 5% vs 2023 (€ 120,458) Unchanged	€ 109,568 Land & buildings 2025: € 109,568 ▼ 4% vs 2024 (€ 114,083) Unchanged	▼ 4%
Retained profit	€ 202,295 Retained profit 2022: € 202,295 First fiscal year in the series	€ 272,971 Retained profit 2023: € 272,971 ▲ 35% vs 2022 (€ 202,295) Favourable step	€ 324,361 Retained profit 2024: € 324,361 ▲ 19% vs 2023 (€ 272,971) Favourable step	€ 414,736 Retained profit 2025: € 414,736 ▲ 28% vs 2024 (€ 324,361) Favourable step	▲ 28%
Dividend	€ 20,000 Dividend 2022: € 20,000 First fiscal year in the series	€ 20,000 Dividend 2023: € 20,000 Unchanged (€ 20,000) Unchanged	€ 23,529 Dividend 2024: € 23,529 ▲ 18% vs 2023 (€ 20,000) Unchanged	€ 15,000 Dividend 2025: € 15,000 ▼ 36% vs 2024 (€ 23,529) Unchanged	▼ 36%
Bank debt	€ 855,327 Bank debt 2022: € 855,327 First fiscal year in the series	€ 773,293 Bank debt 2023: € 773,293 ▼ 10% vs 2022 (€ 855,327) Favourable step	€ 706,932 Bank debt 2024: € 706,932 ▼ 9% vs 2023 (€ 773,293) Favourable step	€ 639,547 Bank debt 2025: € 639,547 ▼ 10% vs 2024 (€ 706,932) Favourable step	▼ 10%
Balance sheet total	€ 1,114,382 Balance sheet total 2022: € 1,114,382 First fiscal year in the series	€ 1,103,984 Balance sheet total 2023: € 1,103,984 ▼ 1% vs 2022 (€ 1,114,382) Unchanged	€ 1,098,252 Balance sheet total 2024: € 1,098,252 ▼ 1% vs 2023 (€ 1,103,984) Unchanged	€ 1,095,768 Balance sheet total 2025: € 1,095,768 Unchanged (€ 1,098,252) Unchanged

Key figures of Filepharma Invest, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Filepharma Invest?

What happened at Filepharma Invest in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 3, 2026 New annual accounts for financial year 2025: profit of € 105,376 (▲ 41% vs 2024). Source: NBB ↗
Nov 29, 2018 New establishment in Soignies. KBO
Nov 29, 2018 Start of the company according to the CBE. KBO

In short

From € 102,922 profit in 2022 to € 105,376 profit in 2025.

Paid € 84,110 in corporate taxes since 2022.

Best year ever: 2025, with € 105,376 profit.

Paid out € 78,529 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Celine FILECCIA

Filepharma Invest

Pharmacie Fileccia 100%

Behind Filepharma Invest is Celine FILECCIA. It owns 100% of Pharmacie Fileccia itself.

Directors

According to the 2025 annual accounts

Celine FILECCIA

Director

Establishments

Establishment units

Physical locations of this company

Registered office

Chaussée de Bruxelles 133

7061 Soignies

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.

All companies at this address →

PHARMACIE FILECCIA same network

€ 168,957 gross margin · 2025

UNITE FILECCIA

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0714.928.107

VAT number

BE 0714.928.107

Registered office

Chaussée de Bruxelles 133, 7061 Soignies

Names & denominations

Filepharma Invest

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

29 November 2018

Peppol

Active · Active since 18 Dec 2025

Activities · NACE

Activiteiten van hoofdkantoren

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Detailhandel in farmaceutische producten

Verhuur en exploitatie van eigen of geleased residentieel onroerend goed, exclusief sociale woningen

Verhuur en exploitatie van eigen of geleased niet-residentieel onroerend goed, exclusief terreinen

Vervaardiging van farmaceutische grondstoffen

Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering

View on CBE Public ↗ Annual accounts (NBB) ↗

Filepharma Invest

Warning lights

Financials

What happened to Filepharma Invest?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions